6 results on '"Kumari, Anni"'
Search Results
2. Carboxyl-terminal sequences in APOA5 are important for suppressing ANGPTL3/8 activity.
- Author
-
Chen, Yan Q., Ye Yang, Zhen, Eugene Y., Beyer, Thomas P., Hongxia Li, Yi Wen, Ehsani, Mariam, Jackson, Nicholas, Katherine Xie, Hyesoo Jung, Scheithauer, Julia L., Kumari, Anni, Birrane, Gabriel, Russell, Anna M., Balasubramaniam, Deepa, Zhongping Liao, Siegel, Robert W., Yuewei Qian, Ploug, Michael, and Young, Stephen G.
- Subjects
ANGIOPOIETIN-like proteins ,LIPOPROTEIN lipase ,PEPTIDES ,CATALYTIC activity ,CARRIER proteins - Abstract
Apolipoprotein AV (APOA5) lowers plasma triglyceride (TG) levels by binding to the angiopoietin-like protein 3/8 complex (ANGPTL3/8) and suppressing its capacity to inhibit lipoprotein lipase (LPL) catalytic activity and its ability to detach LPL from binding sites within capillaries. However, the sequences in APOA5 that are required for suppressing ANGPTL3/8 activity have never been defined. A clue to the identity of those sequences was the presence of severe hypertriglyceridemia in two patients harboring an APOA5 mutation that truncates APOA5 by 35 residues ("APOA5Δ35"). We found that wild-type (WT) human APOA5, but not APOA5Δ35, suppressed ANGPTL3/8's ability to inhibit LPL catalytic activity. To pursue that finding, we prepared a mutant mouse APOA5 protein lacking 40 C-terminal amino acids ("APOA5Δ40"). Mouse WT-APOA5, but not APOA5Δ40, suppressed ANGPTL3/8's capacity to inhibit LPL catalytic activity and sharply reduced plasma TG levels in mice. WT-APOA5, but not APOA5Δ40, increased intracapillary LPL levels and reduced plasma TG levels in Apoa5-/- mice (where TG levels are high and intravascular LPL levels are low). Also, WT-APOA5, but not APOA5Δ40, blocked the ability of ANGPTL3/8 to detach LPL from cultured cells. Finally, an antibody against a synthetic peptide corresponding to the last 26 amino acids of mouse APOA5 reduced intracapillary LPL levels and increased plasma TG levels in WT mice. We conclude that C-terminal sequences in APOA5 are crucial for suppressing ANGPTL3/8 activity in vitro and for regulating intracapillary LPL levels and plasma TG levels in vivo. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Hydrogel-Based Drug Delivery for Cancer Immunotherapy: Design, Advances, and Applications - A Comprehensive Review.
- Author
-
Venkatesh, Uriti Sri, Kumar, Anil, Ghosh, Tanmay, Ponmalai, Srinivasan, Kumar, Sinha Ashutosh, Kumari, Anni, Avasthi, Garima, Pathak, Vishal, and Singh, Neha
- Subjects
VACCINE effectiveness ,DRUG delivery systems ,IMMUNOTHERAPY ,VACCINE development ,ANTINEOPLASTIC agents - Abstract
Hydrogels have attracted significant attention in the realm of vaccine development due to their unique attributes, which include compatibility with living tissues, a considerable water content, and modifiable physical traits. This article examines the utilisation of hydrogels in the process of vaccine development. Hydrogels function as adaptable vehicles for the transportation of vaccines, providing benefits including prolonged release, safeguarding against degradation of antigens, and precise administration to particular cells or tissues. The application of hydrogel matrices to encapsulate antigens and adjuvants has the potential to improve the stability, immunogenicity, and effectiveness of vaccines. Due to their distinctive attributes, they are exemplary contenders for drug delivery systems. Hydrogels are specifically engineered to facilitate the co-administration of therapeutic agents, including immune cells, cytokines, and monoclonal antibodies, with the aim of augmenting the therapeutic effectiveness of malignancy. Moreover, hydrogel-based vaccines can be administered via various routes, including injection, patches, or implants, providing flexibility and convenience in vaccination. Challenges such as formulation optimization, manufacturing scalability, and regulatory approval remain, but the continued research and development of hydrogel-based vaccines hold promise for improving vaccination strategies and addressing global health challenges. [ABSTRACT FROM AUTHOR]
- Published
- 2024
4. Inverse effects of APOC2 and ANGPTL4 on the conformational dynamics of lid-anchoring structures in lipoprotein lipase.
- Author
-
Kumari, Anni, Grønnemose, Anne Louise, Kristensen, Kristian K., Winther, Anne-Marie L., Young, Stephen G., Jørgensen, Thomas J. D., and Ploug, Michael
- Subjects
- *
LIPOPROTEIN lipase , *APOLIPOPROTEIN C , *ANGIOPOIETIN-like proteins , *HYDROGEN-deuterium exchange , *LIPOPROTEINS , *CATALYTIC reforming - Abstract
The lipolytic processing of triglyceride-rich lipoproteins (TRLs) by lipoprotein lipase (LPL) is crucial for the delivery of dietary lipids to the heart, skeletal muscle, and adipose tissue. The processing of TRLs by LPL is regulated in a tissue-specific manner by a complex interplay between activators and inhibitors. Angiopoietin-like protein 4 (ANGPTL4) inhibits LPL by reducing its thermal stability and catalyzing the irreversible unfolding of LPL's a/ß-hydrolase domain. We previously mapped the ANGPTL4 binding site on LPL and defined the downstream unfolding events resulting in LPL inactivation. The binding of LPL to glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 protects against LPL unfolding. The binding site on LPL for an activating cofactor, apolipoprotein C2 (APOC2), and the mechanisms by which APOC2 activates LPL have been unclear and controversial. Using hydrogen-deuterium exchange/mass spectrometry, we now show that APOC2's C-terminal a-helix binds to regions of LPL surrounding the catalytic pocket. Remarkably, APOC2's binding site on LPL overlaps with that for ANGPTL4, but their effects on LPL conformation are distinct. In contrast to ANGPTL4, APOC2 increases the thermal stability of LPL and protects it from unfolding. Also, the regions of LPL that anchor the lid are stabilized by APOC2 but destabilized by ANGPTL4, providing a plausible explanation for why APOC2 is an activator of LPL, while ANGPTL4 is an inhibitor. Our studies provide fresh insights into the molecular mechanisms by which APOC2 binds and stabilizes LPL--and properties that we suspect are relevant to the conformational gating of LPL's active site. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. The Importance of Lipoprotein Lipase Regulation in Atherosclerosis.
- Author
-
Kumari, Anni, Kristensen, Kristian K., Ploug, Michael, and Winther, Anne-Marie Lund
- Subjects
LIPOPROTEIN lipase ,ANGIOPOIETIN-like proteins ,LDL cholesterol ,LOW density lipoproteins ,BLOOD lipoproteins - Abstract
Lipoprotein lipase (LPL) plays a major role in the lipid homeostasis mainly by mediating the intravascular lipolysis of triglyceride rich lipoproteins. Impaired LPL activity leads to the accumulation of chylomicrons and very low-density lipoproteins (VLDL) in plasma, resulting in hypertriglyceridemia. While low-density lipoprotein cholesterol (LDL-C) is recognized as a primary risk factor for atherosclerosis, hypertriglyceridemia has been shown to be an independent risk factor for cardiovascular disease (CVD) and a residual risk factor in atherosclerosis development. In this review, we focus on the lipolysis machinery and discuss the potential role of triglycerides, remnant particles, and lipolysis mediators in the onset and progression of atherosclerotic cardiovascular disease (ASCVD). This review details a number of important factors involved in the maturation and transportation of LPL to the capillaries, where the triglycerides are hydrolyzed, generating remnant lipoproteins. Moreover, LPL and other factors involved in intravascular lipolysis are also reported to impact the clearance of remnant lipoproteins from plasma and promote lipoprotein retention in capillaries. Apolipoproteins (Apo) and angiopoietin-like proteins (ANGPTLs) play a crucial role in regulating LPL activity and recent insights into LPL regulation may elucidate new pharmacological means to address the challenge of hypertriglyceridemia in atherosclerosis development. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
6. Evolution and Medical Significance of LU Domain−Containing Proteins.
- Author
-
Leth, Julie Maja, Leth-Espensen, Katrine Zinck, Kristensen, Kristian Kølby, Kumari, Anni, Lund Winther, Anne-Marie, Young, Stephen G., and Ploug, Michael
- Subjects
GLYCOLIPIDS ,PROTEIN domains ,MEMBRANE proteins ,PROTEINS ,LIGAND binding (Biochemistry) ,MISSENSE mutation - Abstract
Proteins containing Ly6/uPAR (LU) domains exhibit very diverse biological functions and have broad taxonomic distributions in eukaryotes. In general, they adopt a characteristic three-fingered folding topology with three long loops projecting from a disulfide-rich globular core. The majority of the members of this protein domain family contain only a single LU domain, which can be secreted, glycolipid anchored, or constitute the extracellular ligand binding domain of type-I membrane proteins. Nonetheless, a few proteins contain multiple LU domains, for example, the urokinase receptor uPAR, C4.4A, and Haldisin. In the current review, we will discuss evolutionary aspects of this protein domain family with special emphasis on variations in their consensus disulfide bond patterns. Furthermore, we will present selected cases where missense mutations in LU domain−containing proteins leads to dysfunctional proteins that are causally linked to genesis of human disease. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.